Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Mary F. Mulcahy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6103-0989; OpenAlex author ID A5036972230. Sources: ClinicalTrials.gov.

Their work

Papers
13 (first author 2, last author 1)
Trials
4 (principal investigator on 2)
Grants
0
Labs led
0
Collaborators
63
Papers, trials and grants by year

2005: 1 trial · 2006: none · 2007: none · 2008: 1 trial · 2009: none · 2010: none · 2011: 3 papers · 2012: 1 paper, 1 trial · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 13

  1. Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. Co-author DOI 10.1038/s41591-026-04327-4↗
  2. KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase Trials. Co-author DOI 10.3390/cancers18132037↗
  3. Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic … Co-author DOI 10.1016/j.esmoop.2025.105122↗
  4. Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC). Co-author DOI 10.1038/s41416-023-02344-5↗
  5. Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704. Co-author DOI 10.1016/j.ijrobp.2020.08.042↗
  6. Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study. Last author DOI 10.1634/theoncologist.2019-0473↗
  7. Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unres… Co-author DOI 10.1007/s12029-016-9821-9↗
  8. 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). Co-author DOI 10.1093/jnci/dju185↗
  9. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. First author DOI 10.1007/s11605-012-2064-6↗
  10. A Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer. Co-author PMID 22888387↗
  11. Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized panc… First author DOI 10.1016/j.ijrobp.2010.02.030↗
  12. Change in the growth rate of localized pancreatic adenocarcinoma in response to gemcitabine, bevacizumab, and radiation therapy on MDCT. Co-author DOI 10.1016/j.ijrobp.2010.05.060↗
  13. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients. Co-author DOI 10.1586/era.11.125↗

Trials 4

  1. Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery Principal investigator NCT01473940↗
  2. AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Study chair NCT00427349↗
  3. Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer Principal investigator NCT00281996↗
  4. Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors NCT00227773↗

Closest collaborators

The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Devalingam Mahalingam · 4 shared papers, 2023–2026 · strength 0.86
  2. Al B. Benson · 6 shared papers, 2011–2026 · strength 0.74
  3. Sheetal Mehta Kircher · 4 shared papers, 2011–2026 · strength 0.60
  4. Aparna Kalyan · 3 shared papers, 2020–2026 · strength 0.57
  5. Benedito A. Carneiro · 2 shared papers, 2025–2026 · strength 0.41
  6. Andrès M.R. Cervantes · 2 shared papers, 2025–2026 · strength 0.41
  7. Andrew L. Coveler · 2 shared papers, 2025–2026 · strength 0.41
  8. Vaibhav Sahai · 2 shared papers, 2025–2026 · strength 0.41
  9. Tarık Demir · 1 shared paper, 2026 · strength 0.29
  10. Dılşa Mızrak Kaya · 1 shared paper, 2026 · strength 0.29
  11. Rachna T. Shroff · 1 shared paper, 2026 · strength 0.22
  12. Noelle K. LoConte · 1 shared paper, 2026 · strength 0.22
  13. Anne Ploquin · 1 shared paper, 2026 · strength 0.22
  14. Petr Kavan · 1 shared paper, 2026 · strength 0.22
  15. Ryan Michael Carr · 1 shared paper, 2026 · strength 0.22
  16. Tanios Bekaii‐Saab · 1 shared paper, 2026 · strength 0.22
  17. Simon Pernot · 1 shared paper, 2026 · strength 0.22
  18. Charles D. Lopez · 1 shared paper, 2026 · strength 0.22
  19. Alexander Grenander Raufi · 1 shared paper, 2025 · strength 0.19
  20. Steven Francis Powell · 1 shared paper, 2025 · strength 0.19
  21. Marisol Huerta · 1 shared paper, 2025 · strength 0.19
  22. Ludimila L. Cavalcante · 1 shared paper, 2025 · strength 0.19
  23. Anwaar Saeed · 1 shared paper, 2025 · strength 0.19
  24. Jordan D. Berlin · 1 shared paper, 2025 · strength 0.19
  25. Kyle Holen · 1 shared trial · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.